BACKGROUND: In the context of 2009 pandemic influenza (H1N1) virus infection (pandemic H1N1 influenza), identifying correlates of the severity of disease is critical to guiding the implementation of antiviral strategies, prioritization of vaccination efforts and planning of health infrastructure. The objective of this study was to identify factors correlated with severity of disease in confirmed cases of pandemic H1N1 influenza. METHODS: This cumulative case-control study included all laboratory-confirmed cases of pandemic H1N1 influenza among residents of the province of Manitoba, Canada, for whom the final location of treatment was known. Severe cases were defined by admission to a provincial intensive care unit (ICU). Factors associated with severe disease necessitating admission to the ICU were determined by comparing ICU cases with two control groups: patients who were admitted to hospital but not to an ICU and those who remained in the community. RESULTS: As of Sept. 5, 2009, there had been 795 confirmed cases of pandemic H1N1 influenza in Manitoba for which the final treatment location could be determined. The mean age of individuals with laboratory-confirmed infection was 25.3 (standard deviation 18.8) years. More than half of the patients (417 or 52%) were female, and 215 (37%) of 588 confirmed infections for which ethnicity was known occurred in First Nations residents. The proportion of First Nations residents increased with increasing severity of disease (116 [28%] of 410 community cases, 74 [54%] of 136 admitted to hospital and 25 [60%] of 42 admitted to an ICU; p<0.001), as did the presence of an underlying comorbidity (201 [35%] of 569 community cases, 103 [57%] of 181 admitted to hospital and 34 [76%] of 45 admitted to an ICU; p<0.001). The median interval from onset of symptoms to initiation of antiviral therapy was 2 days (interquartile range, IQR 1-3) for community cases, 4 days (IQR 2-6) for patients admitted to hospital and 6 days (IQR 4-9) for those admitted to an ICU (p<0.001). In a multivariable logistic model, the interval from onset of symptoms to initiation of antiviral therapy (odds ratio [OR] 8.24, 95% confidence interval [CI] 2.82-24.1), First Nations ethnicity (OR 6.52, 95% CI 2.04-20.8) and presence of an underlying comorbidity (OR 3.19, 95% CI 1.07-9.52) were associated with increased odds of admission to the ICU (i.e., severe disease) relative to community cases. In an analysis of ICU cases compared with patients admitted to hospital, First Nations ethnicity (OR 3.23, 95% CI 1.04-10.1) was associated with increased severity of disease. INTERPRETATION: Severe pandemic H1N1 influenza necessitating admission to the ICU was associated with a longer interval from onset of symptoms to treatment with antiviral therapy and with the presence of an underlying comorbidity. First Nations ethnicity appeared to be an independent determinant of severe infection. Despite these associations, the cause and outcomes of pandemic HINI influenza may involve many complex and interrelated factors, all of which require further research and analysis.
BACKGROUND: In the context of 2009 pandemic influenza (H1N1) virus infection (pandemic H1N1 influenza), identifying correlates of the severity of disease is critical to guiding the implementation of antiviral strategies, prioritization of vaccination efforts and planning of health infrastructure. The objective of this study was to identify factors correlated with severity of disease in confirmed cases of pandemic H1N1 influenza. METHODS: This cumulative case-control study included all laboratory-confirmed cases of pandemic H1N1 influenza among residents of the province of Manitoba, Canada, for whom the final location of treatment was known. Severe cases were defined by admission to a provincial intensive care unit (ICU). Factors associated with severe disease necessitating admission to the ICU were determined by comparing ICU cases with two control groups: patients who were admitted to hospital but not to an ICU and those who remained in the community. RESULTS: As of Sept. 5, 2009, there had been 795 confirmed cases of pandemic H1N1 influenza in Manitoba for which the final treatment location could be determined. The mean age of individuals with laboratory-confirmed infection was 25.3 (standard deviation 18.8) years. More than half of the patients (417 or 52%) were female, and 215 (37%) of 588 confirmed infections for which ethnicity was known occurred in First Nations residents. The proportion of First Nations residents increased with increasing severity of disease (116 [28%] of 410 community cases, 74 [54%] of 136 admitted to hospital and 25 [60%] of 42 admitted to an ICU; p<0.001), as did the presence of an underlying comorbidity (201 [35%] of 569 community cases, 103 [57%] of 181 admitted to hospital and 34 [76%] of 45 admitted to an ICU; p<0.001). The median interval from onset of symptoms to initiation of antiviral therapy was 2 days (interquartile range, IQR 1-3) for community cases, 4 days (IQR 2-6) for patients admitted to hospital and 6 days (IQR 4-9) for those admitted to an ICU (p<0.001). In a multivariable logistic model, the interval from onset of symptoms to initiation of antiviral therapy (odds ratio [OR] 8.24, 95% confidence interval [CI] 2.82-24.1), First Nations ethnicity (OR 6.52, 95% CI 2.04-20.8) and presence of an underlying comorbidity (OR 3.19, 95% CI 1.07-9.52) were associated with increased odds of admission to the ICU (i.e., severe disease) relative to community cases. In an analysis of ICU cases compared with patients admitted to hospital, First Nations ethnicity (OR 3.23, 95% CI 1.04-10.1) was associated with increased severity of disease. INTERPRETATION: Severe pandemic H1N1 influenza necessitating admission to the ICU was associated with a longer interval from onset of symptoms to treatment with antiviral therapy and with the presence of an underlying comorbidity. First Nations ethnicity appeared to be an independent determinant of severe infection. Despite these associations, the cause and outcomes of pandemic HINI influenza may involve many complex and interrelated factors, all of which require further research and analysis.
Authors: Enrique Gonzalez; Hemant Kulkarni; Hector Bolivar; Andrea Mangano; Racquel Sanchez; Gabriel Catano; Robert J Nibbs; Barry I Freedman; Marlon P Quinones; Michael J Bamshad; Krishna K Murthy; Brad H Rovin; William Bradley; Robert A Clark; Stephanie A Anderson; Robert J O'connell; Brian K Agan; Seema S Ahuja; Rosa Bologna; Luisa Sen; Matthew J Dolan; Sunil K Ahuja Journal: Science Date: 2005-01-06 Impact factor: 47.728
Authors: F Y Aoki; M D Macleod; P Paggiaro; O Carewicz; A El Sawy; C Wat; M Griffiths; E Waalberg; P Ward Journal: J Antimicrob Chemother Date: 2003-01 Impact factor: 5.790
Authors: Anand Kumar; Ryan Zarychanski; Ruxandra Pinto; Deborah J Cook; John Marshall; Jacques Lacroix; Tom Stelfox; Sean Bagshaw; Karen Choong; Francois Lamontagne; Alexis F Turgeon; Stephen Lapinsky; Stéphane P Ahern; Orla Smith; Faisal Siddiqui; Philippe Jouvet; Kosar Khwaja; Lauralyn McIntyre; Kusum Menon; Jamie Hutchison; David Hornstein; Ari Joffe; Francois Lauzier; Jeffrey Singh; Tim Karachi; Kim Wiebe; Kendiss Olafson; Clare Ramsey; Sat Sharma; Peter Dodek; Maureen Meade; Richard Hall; Robert A Fowler Journal: JAMA Date: 2009-10-12 Impact factor: 56.272
Authors: Guillermo Domínguez-Cherit; Stephen E Lapinsky; Alejandro E Macias; Ruxandra Pinto; Lourdes Espinosa-Perez; Alethse de la Torre; Manuel Poblano-Morales; Jose A Baltazar-Torres; Edgar Bautista; Abril Martinez; Marco A Martinez; Eduardo Rivero; Rafael Valdez; Guillermo Ruiz-Palacios; Martín Hernández; Thomas E Stewart; Robert A Fowler Journal: JAMA Date: 2009-10-12 Impact factor: 56.272
Authors: Steven A R Webb; Ville Pettilä; Ian Seppelt; Rinaldo Bellomo; Michael Bailey; David J Cooper; Michelle Cretikos; Andrew R Davies; Simon Finfer; Peter W J Harrigan; Graeme K Hart; Belinda Howe; Jonathan R Iredell; Colin McArthur; Imogen Mitchell; Siouxzy Morrison; Alistair D Nichol; David L Paterson; Sandra Peake; Brent Richards; Dianne Stephens; Andrew Turner; Michael Yung Journal: N Engl J Med Date: 2009-10-08 Impact factor: 91.245
Authors: Seema Jain; Laurie Kamimoto; Anna M Bramley; Ann M Schmitz; Stephen R Benoit; Janice Louie; David E Sugerman; Jean K Druckenmiller; Kathleen A Ritger; Rashmi Chugh; Supriya Jasuja; Meredith Deutscher; Sanny Chen; John D Walker; Jeffrey S Duchin; Susan Lett; Susan Soliva; Eden V Wells; David Swerdlow; Timothy M Uyeki; Anthony E Fiore; Sonja J Olsen; Alicia M Fry; Carolyn B Bridges; Lyn Finelli Journal: N Engl J Med Date: 2009-10-08 Impact factor: 91.245
Authors: Elizabeth C Lowcock; Laura C Rosella; Julie Foisy; Allison McGeer; Natasha Crowcroft Journal: Am J Public Health Date: 2012-06-14 Impact factor: 9.308
Authors: Deborah L Thompson; Jessica Jungk; Emily Hancock; Chad Smelser; Michael Landen; Megin Nichols; David Selvage; Joan Baumbach; Mack Sewell Journal: Am J Public Health Date: 2011-07-21 Impact factor: 9.308
Authors: Patrick Gérardin; Rachid El Amrani; Béatrice Cyrille; Marc Gabrièle; Philippe Guillermin; Malik Boukerrou; Brahim Boumahni; Hanitra Randrianaivo; Arnaud Winer; Jean-Fabien Rouanet; Michel Bohrer; Marie-Christine Jaffar-Bandjee; Pierre-Yves Robillard; Georges Barau; Alain Michault Journal: PLoS One Date: 2010-05-28 Impact factor: 3.240